49 results about "Right ventricular hypertrophy" patented technology

In some aspects, the disclosure relates to GDF / BMP antagonists and methods of using GDF / BMP antagonists to treat, prevent, or reduce the progression rate and / or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and / or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF / BMP antagonist to treat, prevent, or reduce the progression rate and / or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF / BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.

In some aspects, the invention teaches pharmaceutical compositions that include a TGF-beta ligand trap, and methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-beta signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-beta ligand trap to reduce right ventricular systolic pressure in a subject.

The present invention is concerned with deuterium-enriched pyrimidine compounds of formula 1, their derivatives and pharmaceutically acceptable salts and methods of use thereoffor the prevention and treatment of neuroendocrine neoplasia including metastasis and fibrosis, fibrotic processes associated with neuroendocrine cell dysregulation for example Crohn's disease, pulmonary arterial hypertension, pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD), right ventricular hypertrophy, pulmonary vascular remodeling, asthma, cystic fibrosis, hypertension, ischemic stroke, angina pectoris, congestive heart failure, arrhythmia, arterial fibrillation, neurodenerative diseases, gastrointestinal disorders , stress disorders, obsessive compulsive disorders, demyelinating diseases, cereberal vascular disorders, bronchoconstriction, vasodilation, smooth muscle contraction, brain disorders, vascular disorders, neuropathological diseases and cardiovascular system regulation.

The invention relates to new pharmacological effects of a compound pinocembrin and an application of pinocembrin to preparation of products for preventing, relieving and / or treating pulmonary hypertension and complications thereof. Pinocembrin has the beneficial effects that pinocembrin has the pharmacological effects of relaxing pulmonary arteries, reducing the pulmonary artery pressure, protecting pulmonary vessels from injuries caused by pulmonary hypertension, restoring lung tissue functions, repairing heart and liver injuries, alleviating right ventricular hypertrophy and enlargement, improving heart failure and liver functions, obviously reducing the mortality of animals with pulmonary hypertension and preventing and treating pulmonary hypertension and complications thereof; pinocembrin is an active monomer separated from a natural product propolis, achieves complete synthesis at present, has good application and development prospects, is an ideal compound for treating pulmonary hypertension and complications thereof and can be applied to preparation of the products for preventing, relieving and / or treating pulmonary hypertension and complications thereof, such as chronic obstructive emphysema, chronic pulmonary heart diseases, right heart failure and liver function injuries.

Methods are provided for treating pathologies associated with hypoxia with an MIF inhibitor. Methods are also provided for treating a subject having, or at risk for pulmonary hypertension, with an MIF inhibitor. Methods are also provided for reating a subject having, or at risk from, a CNS disorder associated with hypoxia, with an MIF inhibitor. Methods are also provided of treating severe chronic lung disease, hypoxia-induced right ventricular hypertrophy or hypoxia-induced pulmonary vascular remodeling with an MIF inhibitor. Methods of diagnosing a subject with pulmonary hypertension are also provided.

The invention relates to the field of pharmaceutical chemistry and particularly provides a polydatin (PD) derivative containing a NO (nitric oxide) donor. A PD (3,4',5-trihydroxystilbene-3-beta-D-glucoside)4' hydroxyl group and a corresponding nitrate ester are subjected to chemical reaction so as to generate the NO donor type PD derivative which is in ester bond connection. After being absorbed into a lung tissue, the compound is subjected to biological transformation and ester bond breakage so that a bulk pharmaceutical chemical PD and the NO donor are dissociated, the NO donor can release NO slowly, and NO and PD can play roles of reducing pulmonary hypertension, relieving right ventricular hypertrophy, improving the pulmonary vascular endothelium function and resisting lipid peroxide cooperatively. The NO donor type PD derivative has an application in the aspect of preparing medicaments for preventing or treating pulmonary hypertension and high altitude pulmonary edema diseases caused by oxygen deficiency.

The present invention is concerned with deuterium-enriched pyrimidine compounds of formula I, their derivatives and pharmaceutically acceptable salts and methods of use thereof,The compounds of formula I are useful for the prevention and treatment of liver fibrosis and cirrhosis, hepatocellular carcinoma, neuroendrcrine neoplasia including metastasis and fibrosis fibrotic processes associated with neuroendocrine cell dysregulation for example Crohn's disease, pulmonary arterial hypertension, pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD), right ventricular hypertrophy, pulmonary vascular remodeling, asthma, cystic fibrosis, hypertension, ischemic stroke, angina pectoris, congestive heart failure, arrhythmia, arterial fibrillation, gastrointestinal disorders, anxiety, depression, stress disorders, post-traumatic stress disorder, obsessive compulsive disorders, demyelinating diseases, acute or chronic cerebrovascular damage, cerebral infarction, subarachanoid hemorrhage, and cerebral edema, neuropathological diseases and cardiovascular system regulation.